Yes, butalbital is a barbiturate. It is classified as an intermediate-acting barbiturate and works by enhancing the activity of GABA, the brain’s primary calming chemical. The FDA labels it explicitly as “a barbiturate” and “a central nervous system (CNS) depressant.” You’ll almost never find butalbital prescribed on its own. It’s combined with other ingredients in medications used primarily for tension headaches.
How Butalbital Works in the Brain
Like all barbiturates, butalbital latches onto GABA receptors in the brain and increases the flow of chloride ions into nerve cells. This makes neurons less likely to fire, which slows down nervous system activity overall. The result is muscle relaxation, reduced anxiety, and sedation. Butalbital also appears to block certain excitatory receptors in the brain, which may contribute to its pain-relieving effects.
This mechanism is what makes barbiturates effective but also what makes them risky. The same process that calms muscle tension and eases a headache can, at higher doses, suppress breathing and produce euphoria.
Common Medications Containing Butalbital
Butalbital is prescribed almost exclusively as part of combination products. The most well-known is Fioricet, which contains 50 mg of butalbital, 300 mg of acetaminophen, and 40 mg of caffeine per capsule. Fiorinal uses the same butalbital dose but swaps acetaminophen for aspirin. Some formulations also include codeine.
These combinations are designed for tension headaches. The butalbital relaxes muscle contractions, the pain reliever targets the headache itself, and the caffeine helps constrict blood vessels and may speed absorption of the other ingredients. The recommended dose is one or two tablets every four hours, with a maximum of six tablets in a 24-hour period.
Controlled Substance Status
Butalbital’s scheduling is a bit unusual. The drug itself is a Schedule III controlled substance under federal law, meaning it has recognized medical use but carries a moderate risk of dependence. However, certain butalbital combination products, like Fioricet (butalbital with acetaminophen and caffeine), have been granted exempt status by the DEA. This means they can be prescribed without some of the restrictions that apply to other Schedule III drugs. Fiorinal, the aspirin-based version, does not share this exemption and remains fully scheduled. Some states apply their own, stricter controls regardless of federal exemptions.
Side Effects and Risks
The most common side effects are what you’d expect from a CNS depressant: drowsiness, dizziness, lightheadedness, and a feeling of sedation. Some people experience nausea. At higher doses, butalbital can cause euphoria, which is part of what gives it abuse potential.
The more serious risk is respiratory depression, where breathing becomes dangerously slow. This risk increases sharply when butalbital is combined with alcohol, benzodiazepines, opioids, or other sedating substances. These combinations can produce additive effects on the central nervous system, meaning two moderate doses of different depressants can act like one large dose. MAO inhibitors, a class of antidepressant, can also intensify butalbital’s effects.
Butalbital is contraindicated in people with porphyria, a group of disorders affecting the blood and nervous system, because barbiturates can trigger acute and potentially life-threatening episodes. Anyone with an acetaminophen allergy should also avoid Fioricet and similar formulations.
Dependence and Withdrawal
Physical dependence is a real concern with butalbital, particularly with regular use over weeks or months. This is a trait butalbital shares with other intermediate-acting barbiturates like pentobarbital and secobarbital. Your body adapts to the drug’s presence, and stopping abruptly can trigger withdrawal.
Barbiturate withdrawal symptoms range from uncomfortable to dangerous. Mild withdrawal can include weakness, tremor, anxiety, insomnia, nausea, and loss of appetite. More severe withdrawal can escalate to disorientation, visual and auditory hallucinations, dangerously high fever, and seizures. In the most extreme cases, barbiturate withdrawal can cause cardiovascular collapse and death. Research published in Brain Communications specifically names butalbital as one of the intermediate-acting barbiturates associated with severe withdrawal reactions.
This is why stopping butalbital after regular use should always be done gradually under medical supervision, with the dose tapered down rather than cut off suddenly.
Why Butalbital Is Less Common Today
Barbiturates were once the go-to drugs for anxiety, insomnia, and seizures, but they’ve been largely replaced by safer alternatives. Benzodiazepines and newer sleep medications took over most of those roles because they have a wider margin between an effective dose and a dangerous one. Butalbital is one of the last barbiturates still in regular clinical use, surviving mainly because of its specific niche in treating tension headaches. Even in that role, many headache specialists prefer triptans or other options that don’t carry the same dependence risk.
The toxic dose of butalbital is approximately 1 gram, which is only 20 of the standard 50 mg tablets. That narrow safety margin is characteristic of barbiturates and is one of the main reasons the broader drug class fell out of favor.